updated 4/6/2011 12:46:48 PM ET 2011-04-06T16:46:48

  • At Genmab A/S' Annual General Meeting held today on April 6, 2011 the Annual Report for 2010 was approved
  • Discharge was given to the Board of Directors and the Executive Management and the year's loss was carried forward
  • PricewaterhouseCoopers was re-elected as auditor of the Company
  • The proposal from the Board of Directors on general guidelines for incentive-based remuneration, the proposal on the Board of Directors' remuneration for 2011 and the proposals to amend Article 4A and Article 12 of the Articles of Association were adopted
  • A new member was elected to the Board of Directors and two members of the Board of Directors were re-elected

COPENHAGEN, Denmark, April 6, 2011 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) held its Annual General Meeting, today April 6, 2011 at 2:00 PM at Radisson Blu Scandinavia Hotel, Copenhagen, Amager Boulevard 70, DK-2300 Copenhagen S, Denmark.

At the meeting Chairman of the Board of Directors Dr. Michael B. Widmer gave – on behalf of the Board of Directors – a report on the Company's activities during the past year. Chief Executive Officer Jan van de Winkel presented plans for the year ahead, and Chief Financial Officer David Eatwell presented the Annual Report for 2010 endorsed by the auditors. The report was approved and discharge was given to the Board of Directors and the Executive Management.

It was decided that the year's loss of DKK 279 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report.

PricewaterhouseCoopers Statsautoriseret Revisionsaktieselskab A/S was re-elected as the Company's auditor.

The General Meeting adopted the proposals from the Board of Directors, as follows:

  • The proposal to adopt revised general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management.
  • The proposal to adopt the Board of Directors' remuneration for 2011.
  • The proposal to amend Article 4A of the Articles of Association so that the existing authorization to issue nominally DKK 15,000,000 shares is prolonged to five years from the General Meeting.
  • The proposal to amend Article 12 of the Articles of Association so that the General Meeting elected members of the Board of Directors are elected for a period which expires at the Annual General Meeting in the Company in the second year after the year of their election. Furthermore, the reference to Lisa N. Drakeman is deleted.

Toon Wilderbeek were elected to the Board of Directors for a two year period. Michael B. Widmer and Karsten Havkrog Pedersen were both re-elected to the Board of Directors for a two year period.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com .


Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™; HuMax-IL8™; HuMax-TAC™; HuMax-CD38™; HuMax-TF™; HuMax-Her2™; HuMax-Wnt™; HuMax-cMet™, DuoBody™ and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Stock Exchange Release no. 13
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com